MophoSys - ExtraChancen

1D09C3 is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. 1D09C3 binds to MHC class II molecules on the cell surface and selectively kills activated, proliferating tumor cells, which include B-cell and T-cell lymphomas.  In 2004, it was estimated that more than 54,000 people in the U.S. and about 64,000 people in the European Union were diagnosed with non-Hodgkin's lymphoma, the most common form of lymphoma.  CLL is considered a sub-type of non-Hodgkin's lymphoma and is the most common form of adult leukemia in the Western world.  In preclinical studies 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing effect.  A Phase 1 clinical program evaluating 1D09C3 in patients with relapsed or refractory B-cell lymphomas, such as Hodgkin's and non-Hodgkin's lymphomas including CLL, who have failed prior standard therapy is currently underway at major cancer centers in Europe.  1D09C3 has also been granted orphan medicinal product designation for the treatment of Hodgkin's lymphoma.  Additional information on 1D09C3 can be found in the Anticancer Programs section of the Company's Web site at www.gpc-biotech.com.

GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company's lead product candidate - satraplatin - has achieved target enrollment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound.  GPC biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit the Company's Web site at www.gpc-biotech.com.

This press release may contain projections or estimates about plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements. These statements are forward-looking and are subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially depending on a number of factors, including the timing and effects of regulatory actions, the results of clinical trials, the Company's relative success developing and gaining market acceptance for any new products, and the effectiveness of patent protection.  There can be no guarantee that the Phase 1 trials with 1D09C3 will be successfully completed nor that 1D09C3 will be approved for marketing in a timely manner, if at all.  We direct you to the Company's Annual Report on Form 20-F, as amended, for the fiscal year ended December 31, 2004 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the Company's future results, performance and achievements. The Company disclaims any intent or obligation to update these forward-looking statements or the factors that may affect the Company's future results, performance or achievements, even if new information becomes available in the future.


For further information, please contact:

GPC Biotech AG
Fraunhoferstr. 20
82152 Martinsried/Munich, Germany

Martin Braendle (ext. 2693)
Associate Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2600 X2693
ir@gpc-biotech.com  

Published: 12:20 03.02.2006 GMT+1 /HUGIN /Source: MorphoSys AG /GER:
MOR /ISIN: DE0006632003

Ad hoc: MorphoSys veröffentlicht vorläufige Ergebnisse für das Jahr 2005



Die MorphoSys AG (Frankfurt: MOR; Prime Standard Segment; TecDAX) gab
heute vorläufige und ungeprüfte Zahlen gemäß International  Financial
Reporting  Standards  (IFRS)  für  das  Geschäftsjahr  2005  bekannt.
MorphoSys hat seine Prognose für 2005 übertroffen.

MorphoSys erzielte Umsätze  in Höhe  von 33,5 Mio.  Euro (2004:  22,0
Mio. Euro), und  einen Jahresüberschuss  in Höhe von  4,7 Mio.  Euro.
(2004: 0,3 Mio. Euro).

Die bisherige  Unternehmensprognose prognostizierte  Umsätze in  Höhe
von 31,5 Mio. Euro  und einen Jahresüberschuss in  Höhe von 3,5  Mio.
Euro. Die höher  als geplanten Umsätze  und der daraus  resultierende
höhere    Jahresüberschuss    sind    auf    verschiedene    Faktoren
zurückzuführen, wie  früher  als  geplant  erfolgte  erfolgsabhängige
Zahlungen in bestehenden Partnerschaften, welche kurz vor  Jahresende
2005 erreicht wurden.

Alle hier veröffentlichten Ergebnisse  sind vorläufig und  ungeprüft.
MorphoSys wird seinen geprüften  Jahresabschluss am 24. Februar  2006
vorlegen.

ENDE DER AD-HOC-MITTEILUNG